SAN DIEGO--(BUSINESS WIRE)--April 12, 2006--Aethlon Medical, Inc. (OTCBB:AEMD - News), a pioneer in developing therapeutic devices for infectious disease, announced today that it has submitted an Avian Flu-related grant application entitled, "Extracorporeal Treatment of H5N1 Bird Flu Viral Sepsis." The grant was submitted to the National Institutes of Health (NIH) to be directed to the National Institute of Allergy and Infectious Disease (NIAID) as a Phase I Small Business Innovation Grant. The grant application discusses the deployment of the Aethlon Hemopurifier(TM) as a therapy to clear inflammatory cytokines, H5N1 Avian Flu virus and viral fragments that stimulate viral sepsis. Grant collaborators include Dr. Leo L.M. Poon, Assistant Professor at the University of Hong Kong, Department of Microbiology, and Dr. Kevin Gilligan, Senior Scientist at Commonwealth Biotechnologies. There is no assurance that Aethlon will derive grant income related to this research initiative.
